Abstract
In this time of escalating costs there is a compelling need to minimize the costs in time, money and valuable resources spent on preclinical evaluation of new drugs. International harmonisation of requirements is a major step in this direction.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Draper M F and Griffin J P (1980) Draft CPMP Guidelines on Mutagenicity Testing. Arch Toxicol (in press)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer Science+Business Media New York
About this chapter
Cite this chapter
Griffin, J.P. (1981). Preclinical Testing of New Drugs the CPMP Guidelines as a Model for International Harmonisation. In: Wardell, W.M., Velo, G. (eds) Drug Development, Regulatory Assessment, and Postmarketing Surveillance. NATO Advanced Study Institutes Series, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4055-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4055-3_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4057-7
Online ISBN: 978-1-4684-4055-3
eBook Packages: Springer Book Archive